Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AnaptysBio, Inc. (ANAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on immunology therapeutics, AnaptysBio uses these filings to report material events related to its clinical programs, collaborations, capital allocation decisions and strategic plans.
Recent Form 8-K filings describe several categories of information. Some filings report results of operations and financial condition, where AnaptysBio furnishes press releases detailing quarterly financial results and business updates. Others fall under Regulation FD disclosure, such as filings that provide updated corporate investor presentations or slide decks used in conference calls discussing programs like ANB033 or the company’s broader pipeline.
Additional 8-Ks highlight other events, including board authorization of amendments to the company’s stock repurchase plan and the board’s approval of plans to explore separating AnaptysBio’s business into two independent, publicly traded companies by the end of 2026. Filings also cover the company’s Verified Complaint in Delaware Chancery Court against Tesaro and GSK concerning the Collaboration and Exclusive License Agreement for Jemperli, as well as references to Tesaro and GSK’s complaint against AnaptysBio.
For investors analyzing ANAB, these filings help clarify how AnaptysBio reports litigation developments, collaboration terms, royalty monetization arrangements, and major strategic decisions. On Stock Titan, SEC documents are paired with AI-powered summaries that explain the main points of each filing in plain language, highlight notable items such as litigation updates or changes to repurchase plans, and make it easier to scan multiple 8-Ks and other forms without reading every line of legal text.
ANAB filed a Form 144 notice for a planned insider stock sale. The filing shows a planned sale of 2,017 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $88,566.47. The shares relate to restricted stock units acquired from the issuer on January 7, 2026 and paid for in cash. The filing lists 27,688,470 shares of the issuer’s common stock outstanding.
The notice also reports prior transactions by Eric J. Loumeau over the past three months, including sales such as 12,500 shares on December 16, 2025 for $560,800.25 and 10,000 shares on December 17, 2025 for $460,000. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
AnaptysBio, Inc. Chief Medical Officer Paul F. Lizzul reported multiple equity transactions. On January 6, 2026, 6,145 restricted stock units (RSUs) converted into the same number of common shares for no cash cost, and his common stock holdings became 39,448 shares. That day he also received 21,400 new RSUs and a stock option for 29,000 shares.
The new RSUs vest 25% per year starting January 6, 2027, while the option vests 25% on January 6, 2027 and then monthly in equal installments, all contingent on continued service. On January 7, 2026, he sold 2,235 common shares at $45.11 solely to cover tax withholding from the RSU vesting, leaving 37,213 common shares owned directly.
AnaptysBio shareholder Paul F. Lizzul filed a Rule 144 notice to sell 2,235 shares of the company’s common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC, with an aggregate market value of 98138.85, and an approximate sale date of 01/07/2026 on the NASDAQ.
The shares were acquired as restricted stock units from the issuer and paid for in cash on 01/07/2026. The filing notes that 27,688,470 common shares were outstanding. Over the prior three months, Lizzul sold 4,219 common shares on 01/05/2026 for gross proceeds of 189644.05 and 1,500 common shares on 12/22/2025 for gross proceeds of 75000.
AnaptysBio, Inc. reported insider equity activity by President and CEO Daniel Faga. On January 6, 2026, 17,850 restricted stock units (RSUs) were converted into the same number of shares of common stock for no cash consideration. On January 7, 2026, 9,202 shares of common stock were sold at $45.11 per share to cover tax withholding obligations related to RSU vesting, described as a non-discretionary “sell to cover” transaction.
Also on January 6, 2026, Faga received new equity awards consisting of 98,600 RSUs and a stock option for 133,400 shares with an exercise price of $43.91. The RSUs and option awards vest over several years, subject to continued service. After these transactions, Faga beneficially owned 466,787 shares of AnaptysBio common stock directly.
A shareholder of ANAB filed a Rule 144 notice to sell common stock. The planned sale covers 9,202 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $404,059.82 and an approximate sale date of January 7, 2026.
The shares were acquired as restricted stock units from the issuer on January 7, 2026 and paid for in cash. Over the prior three months, the same seller, Daniel Faga, sold 15,309 common shares on January 5, 2026 for gross proceeds of $688,139.55.
AnaptysBio, Inc. Chief Financial Officer Dennis Mulroy reported equity compensation activity and a related share sale. On January 6, 2026, 5,245 restricted stock units settled into common stock, and he then beneficially owned 19,575 common shares. On January 7, 2026, he sold 1,908 common shares at $45.11 per share to cover tax withholding tied to the RSU vesting, which the company notes was a non-discretionary sell-to-cover transaction, leaving him with 17,667 common shares.
On January 6, 2026, he also received new grants of 21,400 restricted stock units and 29,000 stock options with a $43.91 exercise price. The 21,400 RSUs vest 25% annually starting January 6, 2027, and the option vests 25% on January 6, 2027, then monthly in equal installments until fully vested, in each case contingent on continued service.
AnaptysBio investor Dennis Mulroy filed a Form 144 notice to sell 1,908 shares of the company’s common stock, with an aggregate market value of $83,780.28, through Morgan Stanley Smith Barney LLC on NASDAQ around January 7, 2026. These shares were acquired as restricted stock units from the issuer on January 7, 2026 and paid for in cash the same day. Common shares outstanding were 27,688,470.
Over the prior three months, the same seller reported additional common stock sales, including 3,363 shares on January 5, 2026 for gross proceeds of $1,511,166.85, 10,000 shares on December 22, 2025 for $500,000, and 15,725 shares on December 16, 2025 for $705,333.10. By signing the notice, the seller represents not knowing any undisclosed material adverse information about AnaptysBio’s current or prospective operations.
AnaptysBio director Dennis M. Fenton reported new equity awards. On January 6, 2026, he received a stock option for 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share, held directly. The option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, conditioned on continued service.
On the same date, he was also granted 4,000 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock for no cash consideration. These RSUs vest in full on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service to the company.
AnaptysBio director Rita Jain reported new equity awards. On January 6, 2026, she received a stock option covering 5,500 shares of AnaptysBio common stock with an exercise price of $43.91 per share. According to the disclosure, this option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, so long as she continues to provide services to the company.
The filing also shows a grant of 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs are scheduled to vest 100% on the date of AnaptysBio’s 2027 annual meeting of shareholders, again conditioned on continued service. After these awards, Jain beneficially owns 5,500 stock options and 4,000 RSUs directly.
AnaptysBio director Magda Marquet reported new equity awards from the company. On January 6, 2026, she received a stock option to buy 5,500 shares of AnaptysBio common stock at an exercise price of $43.91 per share. This option vests in equal 1/12 installments each month starting on February 6, 2026, as long as she continues providing service to the company on each vesting date.
On the same date, she was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration upon settlement. These RSUs vest as to 100% of the total award on the date of AnaptysBio’s 2027 annual meeting of shareholders, contingent on her continued service through that date.